Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. ANEB
ANEB logo

ANEB

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

ANEB News

Anebulo Pharmaceuticals Reports Q2 Fiscal 2026 Financial Results

Feb 12 2026seekingalpha

Anebulo Pharmaceuticals Announces Voluntary Delisting from Nasdaq

Feb 06 2026Newsfilter

Anebulo Completes Voluntary Tender Offer for 300,000 Shares

Jan 29 2026Newsfilter

UniFirst Corp (UNF) Receives $5.2B Acquisition Proposal from Cintas (CTAS) at 64% Premium

Dec 22 2025Benzinga

U.S. Stocks Rise with Nasdaq Gaining Over 100 Points

Dec 22 2025Benzinga

Biotech Stocks Rise in After-Hours Trading Driven by Data Expectations and Momentum Buying

Dec 11 2025NASDAQ.COM

Anebulo Pharmaceuticals, Inc. Reports Q4 Loss of $2.14 Million

Sep 29 2025NASDAQ.COM

Anebulo Pharmaceuticals Announces Financial Results for Q4 and Fiscal Year 2025 Along with Recent Developments

Sep 29 2025Newsfilter

Anebulo Pharmaceuticals Begins Dosing First Patients in Phase 1 Study of Intravenous Selonabant for Acute Cannabis-Induced Toxicity

Sep 25 2025Newsfilter

M&A Approval Process Explained by FCC Chair in Deal Dispatch

Sep 19 2025Benzinga

Anebulo Pharmaceuticals Provides Update on Private Transaction and Strategic Options

Sep 12 2025Newsfilter

Maxim Group Downgrades Anebulo Pharmaceuticals to Hold

Jul 23 2025Benzinga

Crude Oil Falls; Thermo Fisher Scientific Earnings Top Views

Jul 23 2025Benzinga

Dow Surges Over 200 Points; AT&T Posts Upbeat Earnings

Jul 23 2025Benzinga

Anebulo Pharmaceuticals files to sell 15.15M shares of common stock for holders

Feb 21 2025SeekingAlpha

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates

Feb 14 2025Businesswire